Abstract
Bone Morphogenetic Proteins (BMPs), members of the TGF-β superfamily, are pleiotropic growth factors, known for their role in embryogenesis and bone induction. BMPs signal via two types of serine/threonine kinase BMP receptors (BMPRs), type I, and type II receptors. Ligand binding induces activation of the downstream signalling molecules, the SMADs, which regulate the expression of BMP-responsive genes including those involved in processes such as differentiation, proliferation and apoptosis. BMP signalling is coordinated by both extrinsic and intrinsic mechanisms in order to ensure the control of these important processes. Irregularities however, can occur at any step during the downstream BMP pathway, and aberrations have been implicated in the pathogenesis of several tumour types including: prostate, colorectal, osteosarcomas, myelomas and breast cancer, amongst others. As so many signalling molecules take part in the BMP network, the specific role that these characters play in the pathogenesis of these tumours is rather complex, and hence unclear. In this review, we summarise and consider current literature on BMP signalling, its regulation, and any aberrations in the pathway, focusing on the role of BMPRs, and SMADs on the development, progression and metastasis of solid tumours.
Keywords: Bone morphogenetic protein, signalling, cancer, BMP Receptor, SMAD
Current Signal Transduction Therapy
Title: When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Volume: 4 Issue: 3
Author(s): Sivan Mili Bokobza, Lin Ye and Wen Guo Jiang
Affiliation:
Keywords: Bone morphogenetic protein, signalling, cancer, BMP Receptor, SMAD
Abstract: Bone Morphogenetic Proteins (BMPs), members of the TGF-β superfamily, are pleiotropic growth factors, known for their role in embryogenesis and bone induction. BMPs signal via two types of serine/threonine kinase BMP receptors (BMPRs), type I, and type II receptors. Ligand binding induces activation of the downstream signalling molecules, the SMADs, which regulate the expression of BMP-responsive genes including those involved in processes such as differentiation, proliferation and apoptosis. BMP signalling is coordinated by both extrinsic and intrinsic mechanisms in order to ensure the control of these important processes. Irregularities however, can occur at any step during the downstream BMP pathway, and aberrations have been implicated in the pathogenesis of several tumour types including: prostate, colorectal, osteosarcomas, myelomas and breast cancer, amongst others. As so many signalling molecules take part in the BMP network, the specific role that these characters play in the pathogenesis of these tumours is rather complex, and hence unclear. In this review, we summarise and consider current literature on BMP signalling, its regulation, and any aberrations in the pathway, focusing on the role of BMPRs, and SMADs on the development, progression and metastasis of solid tumours.
Export Options
About this article
Cite this article as:
Bokobza Mili Sivan, Ye Lin and Jiang Guo Wen, When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057485
DOI https://dx.doi.org/10.2174/157436209789057485 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling
Combinatorial Chemistry & High Throughput Screening Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design